FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.
REUTERS/Mike SegarSept 21 (Reuters) - Eli Lilly (LLY.N) on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease.
The agreement enables participating countries in the European Union and European Economic Area to purchase the products directly from Lilly, following authorization, Lilly said, adding that the quantities purchased may vary based on local needs.
While a number of European countries have previously ordered bamlanivimab and etesevimab in the first half of the year and have inventory on hand, this agreement provides access to additional doses for participating countries, should they be needed, Lilly said.
Lilly last week said the U.S. government had bought 388,000 additional doses of its COVID-19 antibody therapy, etesevimab to be paired with the existing supply of bamlanivimab.
Eli Lilly, Mike Segar, Lilly, Manojna, Vinay Dwivedi
Company, REUTERS, Tuesday, European Commission, European Union, European Economic Area, Thomson
Branchburg , New Jersey, Lilly, U.S, Bengaluru